LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments
Brief: Lantern Pharma Confirms Panna Sharma Continues To Serve As President And CEO Alerts Investors To False Third-Party Report
U.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
Lantern Pharma up after FDA allows trial of pediatric brain cancer drug
Brief: Lantern Pharma And Starlight Therapeutics Announce FDA Clearance Of Ind For A Planned Phase 1 Pediatric Cns Cancer Trial Of Star-001
Brief: Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas
Brief: Lantern Pharma Inc - Establishes Ai Center Of Excellence In Bengaluru
Brief: Lantern Pharma Reports Additional Positive Lp-184 Phase 1A Results Showing Durable Disease Control In Heavily Pre-Treated Advanced Cancer Patients
Brief: Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress
U.S. STOCKS ON THE MOVE-Hershey, Eli Lilly, energy stocks
U.S. STOCKS ON THE MOVE-Aqua Metals, Corbus Pharma, Micron
Lantern Pharma rises after early-stage trial win for its cancer drug
Brief: IBN’s BioMedWire Podcast Features Lantern Pharma CEO on AI-Driven Cancer Breakthroughs
Brief: Lantern Pharma Completes FDA Type C Meeting On Pediatric CNS Cancer Trial